PE20110581A1 - Compuestos pirazina como inhibidores de fosfodiesterasa 10 - Google Patents
Compuestos pirazina como inhibidores de fosfodiesterasa 10Info
- Publication number
- PE20110581A1 PE20110581A1 PE2011001035A PE2011001035A PE20110581A1 PE 20110581 A1 PE20110581 A1 PE 20110581A1 PE 2011001035 A PE2011001035 A PE 2011001035A PE 2011001035 A PE2011001035 A PE 2011001035A PE 20110581 A1 PE20110581 A1 PE 20110581A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- pirazine
- iloxi
- methanone
- imidazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRAZINA DE FORMULA (I), DONDE X1, X2, X3, X4 Y X5 SON N O C, EN DONDE NO MAS DE DOS X1, X2, X3, Y X4 SON N; X6, X7, X9 Y X10 SON N O C, EN DONDE NO MAS DE TRES DE X6, X7, X9, Y X10 SON N; X8 Y X11 SON C; Y ES NH, CH(OH), C(=O), ENTRE OTROS; Z ES NH, S, SO, ENTRE OTROS; m ES UN ENTERO DE 0 A 4; n ES 0, 1 O 2; p ES 0, 1 O 2; R1 ES H, F, Cl, ENTRE OTROS; R2 ES F, Cl, OH, ENTRE OTROS; R3 ES F, Cl, CN, ENTRE OTROS; R4 ES F, Cl, CH3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (1H-BENZO[d]IMIDAZOL-2-IL)(4-(3-MORFOLINOPIRAZIN-2-ILOXI)FENIL)-METANONA, (S)-(1H-BENZO[d]IMIDAZOL-2-IL)(4-(3-(4-(1,1,1-TRIFLUORO-2-HIDROXIPROPAN-2-IL)PIPERIDIN-1-IL)PIRAZIN-2-ILOXI)FENIL)METANONA, (1H-BENZO[d]IMIDAZOL-2-IL)(4-(3-CLOROPIRAZIN-2-ILOXI)FENIL)-METANONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA 10 (PDE 10) Y SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD, ESQUIZOFEENIA, DIABETES NO DEPENDIENTE DE INSULINA, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11456708P | 2008-11-14 | 2008-11-14 | |
| US16621209P | 2009-04-02 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110581A1 true PE20110581A1 (es) | 2011-09-03 |
Family
ID=41478512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001035A PE20110581A1 (es) | 2008-11-14 | 2009-11-16 | Compuestos pirazina como inhibidores de fosfodiesterasa 10 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8053438B2 (es) |
| EP (1) | EP2364308B1 (es) |
| JP (1) | JP5746972B2 (es) |
| KR (1) | KR20110083746A (es) |
| CN (1) | CN102300860B (es) |
| AR (1) | AR074358A1 (es) |
| AU (1) | AU2009313768B2 (es) |
| BR (1) | BRPI0922095A2 (es) |
| CA (1) | CA2742993C (es) |
| CL (1) | CL2011001094A1 (es) |
| CO (1) | CO6382157A2 (es) |
| CR (1) | CR20110326A (es) |
| CY (1) | CY1113680T1 (es) |
| DK (1) | DK2364308T3 (es) |
| EA (1) | EA019206B1 (es) |
| ES (1) | ES2397218T3 (es) |
| HR (1) | HRP20130054T1 (es) |
| IL (1) | IL212687A0 (es) |
| MA (1) | MA32889B1 (es) |
| MX (1) | MX2011005100A (es) |
| NZ (1) | NZ592508A (es) |
| PE (1) | PE20110581A1 (es) |
| PL (1) | PL2364308T3 (es) |
| PT (1) | PT2364308E (es) |
| RS (1) | RS52598B (es) |
| SI (1) | SI2364308T1 (es) |
| SM (1) | SMT201200061B (es) |
| TN (1) | TN2011000221A1 (es) |
| TW (1) | TWI396689B (es) |
| WO (1) | WO2010057121A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8637500B2 (en) * | 2008-12-17 | 2014-01-28 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| PL2393360T3 (pl) | 2009-02-05 | 2016-04-29 | Takeda Pharmaceuticals Co | Związki pirydazynonowe |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| EP2536733B1 (en) | 2010-02-19 | 2014-11-26 | Boehringer Ingelheim International GmbH | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| EA022705B1 (ru) | 2010-06-24 | 2016-02-29 | Такеда Фармасьютикал Компани Лимитед | Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ) |
| WO2012018058A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP2601192B1 (en) | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| EP2604597B1 (en) | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
| CN103298792A (zh) | 2010-11-19 | 2013-09-11 | 利亘制药公司 | 杂环胺及其用途 |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| CA2922849A1 (en) * | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
| AP2015008579A0 (en) | 2013-02-05 | 2015-07-31 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| MX2016003843A (es) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| RU2760373C2 (ru) * | 2015-09-18 | 2021-11-24 | Какен Фармасьютикал Ко., Лтд. | Биарильное производное и содержащее его лекарственное средство |
| CN112979661B (zh) * | 2018-01-19 | 2022-05-17 | 苏州信诺维医药科技股份有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
| CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
| US12359128B2 (en) | 2020-12-17 | 2025-07-15 | Merck Patent Gmbh | Heteroaromatic isothiocyanates |
| CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法 |
| EP4524134A1 (en) * | 2022-05-09 | 2025-03-19 | TYK Medicines Inc. | Polycyclic compound and use thereof |
| CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| DK1635828T3 (da) | 2003-04-04 | 2008-08-11 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidin- eller -1,2,3,6-tetrahydropyridinderivater som serotoningenoptagelseshæmmere |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| CN1984901B (zh) * | 2004-05-18 | 2011-02-09 | 先灵公司 | 用作pde4抑制剂的取代的2-喹啉基-*唑 |
| BRPI0511854A (pt) * | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| MX2008001605A (es) | 2005-08-02 | 2008-04-14 | Irm Llc | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. |
| AU2007217750A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| CA2650976A1 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| EP2125786B1 (en) | 2006-12-21 | 2011-03-16 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| AU2008315746A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| AU2009271414A1 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Withdrawn
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 HR HRP20130054AT patent/HRP20130054T1/hr unknown
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 RS RS20120569A patent/RS52598B/sr unknown
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en not_active Ceased
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
-
2011
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110581A1 (es) | Compuestos pirazina como inhibidores de fosfodiesterasa 10 | |
| NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
| NO20076648L (no) | Novel thiophene derivatives | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| PE20090952A1 (es) | Compuestos de pirazol moduladores de raf | |
| NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| CY1117330T1 (el) | Βενζοδιοξινυλ υποκατεστημενα παραγωγα ινδαζολιου | |
| GEP20146046B (en) | Organic compounds | |
| EA201070698A1 (ru) | Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| PE20121335A1 (es) | Compuestos derivados de amida como inhibidores de raf cinasas | |
| MA32604B1 (fr) | Composes organiques | |
| NO20091553L (no) | Fenylderivater og deres anvendelse som immunmodulatorer | |
| ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
| NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
| NO20076638L (no) | Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| NO20055688L (no) | Organiske forbindelser | |
| PE20091077A1 (es) | Derivados de ciclopropilamida con actividad sobre los receptores h3 | |
| PE20091349A1 (es) | Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| ATE368666T1 (de) | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |